Global Patient Derived Xenograft / PDX Models Market to Reach $456.9 Million by 2030
The global market for Patient Derived Xenograft / PDX Models estimated at US$135.8 Million in the year 2022, is projected to reach a revised size of US$456.9 Million by 2030, growing at a CAGR of 16.4% over the analysis period 2022-2030. Mice Model, one of the segments analyzed in the report, is projected to record 17.7% CAGR and reach US$356.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Rat Model segment is readjusted to a revised 12.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $39.7 Million, While China is Forecast to Grow at 15.2% CAGR
The Patient Derived Xenograft / PDX Models market in the U.S. is estimated at US$39.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$76 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15% and 13.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.Select Competitors (Total 38 Featured) -
- Charles River Laboratories International, Inc.
- Crown Bioscience, Inc.
- Epo Berlin-Buch GmbH
- Hera BioLabs
- NexusPharma
- Pharmatest Services Ltd.
- The Jackson Laboratory
- WuXi AppTec Co., Ltd.
- Xentech
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Patient Derived Xenograft/PDX Models - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 5: World Patient Derived Xenograft / PDX Models Market Analysis of Annual Sales in US$ for Years 2014 through 2030
- Table 6: World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 7: World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 9: World 8-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Rat Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 11: World 8-Year Perspective for Rat Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 12: World Recent Past, Current & Future Analysis for Biomarker Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 13: World 8-Year Perspective for Biomarker Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 15: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 17: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 18: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 19: World 8-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 21: USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 22: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 23: USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 24: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 25: USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 27: Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 28: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 29: Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 30: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 31: Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- JAPAN
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 32: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 33: Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 34: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 35: Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 36: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 37: Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- CHINA
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 38: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 39: China 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 40: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 41: China 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 42: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 43: China 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- EUROPE
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 44: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 45: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 46: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 47: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 48: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
- Table 49: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 51: Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- FRANCE
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 52: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 53: France 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 54: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 55: France 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 56: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 57: France 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- GERMANY
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 58: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 59: Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 60: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 61: Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 62: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 63: Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- ITALY
- Table 64: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 65: Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 66: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 67: Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 68: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 69: Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- UNITED KINGDOM
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 70: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 71: UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 72: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 73: UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 74: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 75: UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- REST OF EUROPE
- Table 76: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 77: Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 78: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 79: Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 81: Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- ASIA-PACIFIC
- Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 82: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 83: Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 84: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 85: Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 87: Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
- REST OF WORLD
- Table 88: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 89: Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030
- Table 90: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 91: Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030
- Table 92: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Charles River Laboratories International, Inc.
- Crown Bioscience, Inc.
- Epo Berlin-Buch GmbH
- Hera BioLabs
- NexusPharma
- Pharmatest Services Ltd.
- The Jackson Laboratory
- WuXi AppTec Co., Ltd.
- Xentech
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 192 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 135.8 Million |
Forecasted Market Value ( USD | $ 456.9 Million |
Compound Annual Growth Rate | 16.4% |
Regions Covered | Global |